The small molecule chemical compound cinobufotalin attenuates resistance to DDP by inducing ENKUR expression to suppress MYH9-mediated c-Myc deubiquitination in lung adenocarcinoma-Reference-Cited by-同舟云学术

The small molecule chemical compound cinobufotalin attenuates resistance to DDP by inducing ENKUR expression to suppress MYH9-mediated c-Myc deubiquitination in lung adenocarcinoma

Published:2022-03-16 Issue:10 Volume:43 Page:2687-2695
ISSN:1671-4083
Container-title:Acta Pharmacologica Sinica
language:en
Short-container-title:Acta Pharmacol Sin

Author:

Liu Jia-hao,Yang Hui-ling,Deng Shu-ting,Hu Zhe,Chen Wei-feng,Yan Wei-wei,Hou Ren-tao,Li Yong-hao,Xian Rui-ting,Xie Ying-ying,Su Yun,Wu Li-yang,Xu Ping,Zhu Zhi-bo,Liu Xiong,Deng Yu-ling,Wang Yu-bing,Liu Zhen,Fang Wei-yi

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.nature.com/articles/s41401-022-00890-x.pdf

Reference45 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

2. Deng QD, Lei XP, Zhong YH, Chen MS, Ke YY, Li Z, et al. Triptolide suppresses the growth and metastasis of non-small cell lung cancer by inhibiting β-catenin-mediated epithelial-mesenchymal transition. Acta Pharmacol Sin. 2021;42:1486–97.

3. Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, et al. Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies. Cancer Discov. 2017;7:596–609.

4. Zhang C, Zhang Z, Zhang G, Zhang Z, Luo Y, Wang F, et al. Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma. Cancer Lett. 2020;479:31–41.

5. Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299–311.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-Muscle Myosin II A: Friend or Foe in Cancer?;International Journal of Molecular Sciences;2024-08-30

2. Unveiling the enigmatic role of MYH9 in tumor biology: a comprehensive review;Cell Communication and Signaling;2024-08-27

3. Exploring the nexus between MYH9 and tumors: novel insights and new therapeutic opportunities;Frontiers in Cell and Developmental Biology;2024-08-01

4. Combinational Antitumor Strategies Based on the Active Ingredients of Toad Skin and Toad Venom;Drug Design, Development and Therapy;2024-08

5. Adaptor protein CEMIP reduces the chemosensitivity of small cell lung cancer via activation of an SRC-YAP oncogenic module;Acta Pharmacologica Sinica;2024-07-23